Long time subscribers to Smart Tech Investor may recall our story from last June on exoskeleton technology (“From Comic Books to Reality: Exoskeletons Are Here to Stay“), which recommended three companies that are currently held in our Special Situations Portfolio: Ekso Bionics (EKSO), ReWalk Robotics (RWLK) and Parker Hannifin (PH). Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
All three of our Special Situations Portfolio "cancer stocks" - companies that are on the cutting edge of developing revolutionary treatment for some of the worst forms of cancer, were in the news recently. And almost all of the news was good, with all three stocks moving up smartly as a result. Read More
All three of our Special Situations Portfolio "cancer stocks" - companies that are on the cutting edge of developing revolutionary treatment for some of the worst forms of cancer, were in the news recently. And almost all of the news was good, with all three stocks moving up smartly as a result. Read More
Most analysts avoid calling a top or bottom in the market, knowing the futility of such exercises. But sometimes you can sense when the worst is behind us, which I believe is now the case with energy stocks. Read More
As described in today’s issue of Smart Tech Investor, we are adding the three cancer-fighting companies described in our recent special report, “One Little Shot to Kill Cancer Dead“, to the new STI Special Situations Portfolio. Those stocks are Argos Therapeutics (ARGS), Juno Therapeutics (JUNO), and Ziopharm Oncology (ZIOP). Read More
As described in today’s issue of Smart Tech Investor, we are adding the three cancer-fighting companies described in our recent special report, “One Little Shot to Kill Cancer Dead“, to the new STI Special Situations Portfolio. Those stocks are Argos Therapeutics (ARGS), Juno Therapeutics (JUNO), and Ziopharm Oncology (ZIOP). Read More
We are adding a new portfolio that will focus on stocks that offer tremendous long-term upside potential in fast-growing sectors that require revolutionary technology. Read More
We are adding a new portfolio that will focus on stocks that offer tremendous long-term upside potential in fast-growing sectors that require revolutionary technology. Read More
Three trick questions with inconceivable answers. Read More
Due to last Monday’s Presidents Day holiday the stock market was open for only four days last week instead of the usual five, but that’s all the time it needed to gain nearly 3% – one of its strongest showings in 2016. In fact, after hitting its closing low of… Read More